Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Sebastiani

Showing results (141-150 of 178) with videos related to

Pageof 18
Sort By:
The Journal of Rheumatology|February 1, 2026
Prognostic and Functional Trajectories in Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease: Insights From an Italian Multicenter CohortMarco Fornaro, Donato Lacedonia, Lorenzo Cavagna, et al.
Clinical Rheumatology|July 16, 2016
Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function abilityFlorenzo Iannone, Lugi Sinigaglia, Ennio Giulio Favalli, et al.
Clinical and Experimental Rheumatology|May 19, 2017
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registriesVeronica Codullo, Florenzo Iannone, Luigi Sinigaglia, et al.
Respiratory Medicine|May 16, 2017
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung diseaseJulie Morisset, Eric Vittinghoff, Bo Young Lee, et al.
The Journal of Rheumatology|December 16, 2024
Nintedanib in Rheumatoid Arthritis-Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and DiscontinuationMarco Sebastiani, Gemma Lepri, Claudia Iannone, et al.
Clinical and Experimental Rheumatology|January 31, 2017
Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based studyOlga Addimanda, Massimiliano Marino, Ilaria Farina, et al.
Clinical and Experimental Rheumatology|April 3, 2026
Interstitial lung involvement in rheumatoid arthritis patients treated with abatacept: a prospective observational studyCaterina Vacchi, Marco Sebastiani, Antonio Carletto, et al.
Journal of Autoimmunity|August 10, 2015
Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre studyLuca Quartuccio, Francesca Zuliani, Laura Corazza, et al.
Autoimmunity Reviews|July 17, 2012
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registryFabiola Atzeni, Piercarlo Sarzi-Puttini, Costantino Botsios, et al.
Clinical and Experimental Rheumatology|May 4, 2017
HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC)Massimo Galli, Letizia Oreni, Francesco Saccardo, et al.
Pageof 18

Showing results (141-150 of 178) with videos related to

Sort By:
Pageof 18
The Journal of Rheumatology|February 1, 2026
Prognostic and Functional Trajectories in Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease: Insights From an Italian Multicenter CohortMarco Fornaro, Donato Lacedonia, Lorenzo Cavagna, et al.
Clinical Rheumatology|July 16, 2016
Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function abilityFlorenzo Iannone, Lugi Sinigaglia, Ennio Giulio Favalli, et al.
Clinical and Experimental Rheumatology|May 19, 2017
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registriesVeronica Codullo, Florenzo Iannone, Luigi Sinigaglia, et al.
Respiratory Medicine|May 16, 2017
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung diseaseJulie Morisset, Eric Vittinghoff, Bo Young Lee, et al.
The Journal of Rheumatology|December 16, 2024
Nintedanib in Rheumatoid Arthritis-Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and DiscontinuationMarco Sebastiani, Gemma Lepri, Claudia Iannone, et al.
Clinical and Experimental Rheumatology|January 31, 2017
Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based studyOlga Addimanda, Massimiliano Marino, Ilaria Farina, et al.
Clinical and Experimental Rheumatology|April 3, 2026
Interstitial lung involvement in rheumatoid arthritis patients treated with abatacept: a prospective observational studyCaterina Vacchi, Marco Sebastiani, Antonio Carletto, et al.
Journal of Autoimmunity|August 10, 2015
Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre studyLuca Quartuccio, Francesca Zuliani, Laura Corazza, et al.
Autoimmunity Reviews|July 17, 2012
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registryFabiola Atzeni, Piercarlo Sarzi-Puttini, Costantino Botsios, et al.
Clinical and Experimental Rheumatology|May 4, 2017
HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC)Massimo Galli, Letizia Oreni, Francesco Saccardo, et al.
Pageof 18